Cardiovascular rhythm effects of gamma recombinant DNA interferon

Friess, Gregory G.; Brown, Thomas; Wrenn, Romel C.

doi:10.1007/bf00170873

Cited by 19 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The progressive fall in LVDP caused by IF- (Fig 3) without any change in CK efflux and LV end-diastolic pressure indicates IF-induced negative inotropism, but not a deterioration in the perfused hearts. Interferon-induced negative inotropism [3][4][5] and AV blockade [41][42][43] have been confirmed in clinical practice and those clinical findings in association with the results of the present study imply the IF-induced, dose-dependent inhibition of the L-type Ca channel, although a patch clamp study using single cardiomyocytes is required to confirm this.…”

Section: Discussionsupporting

confidence: 88%

Arrhythmogenic and Inotropic Effects of Interferon Investigated in Perfused and in Vivo Rat Hearts. Influences of Cardiac Hypertrophy and Isoproterenol.

Odashiro

Hiramatsu

Yanagi

et al. 2002

Circ J

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 88%

Arrhythmogenic and Inotropic Effects of Interferon Investigated in Perfused and in Vivo Rat Hearts. Influences of Cardiac Hypertrophy and Isoproterenol.

Odashiro

Hiramatsu

Yanagi

et al. 2002

Circ J

View full text Add to dashboard Cite

“…The results showed no significant alterations in average heart rate or in the frequency of ventricular or supraventricular ectopic beats throughout the course of therapy. 36…”

Section: Discussionmentioning

confidence: 99%

Effect of Chronic Hepatitis C Virus Treatment by Combination Therapy on Cardiovascular System

Biomy

Abdelshafy

Ahmed

et al. 2017

Clin Med Insights Cardiol

View full text Add to dashboard Cite

BACKGROUNDThe prevalence of hepatitis C virus (HCV) in Egypt is quite high, and the combined oral direct-acting antiviral agents (DAAs) may have impressive results.OBJECTIVETo assess the cardiovascular effects of DAAs in patients with HCV.METHODSA total of 170 patients with HCV were divided into 2 groups: first group (100 patients) received triple combination therapy (pegylated interferon alfa, sofosbuvir, and ribavirin, whereas the second group (70 patients) received dual combination therapy (sofosbuvir and simeprevir). Group 1 patients were followed up for 1 year more than 3 visits, whereas group 2 patients were followed up for 6 months more than 2 visits; and the end point of the study was the development of a major cardiovascular event (eg, congestive heart failure, echocardiographic evidence of left ventricular dysfunction, occurrence of significant arrhythmias, or acute coronary syndrome). The following parameters were accomplished: medical history and clinical examination, electrocardiogram, echo-Doppler study, and laboratory investigations.RESULTSNo significant differences were found between the 2 study groups regarding demographic criteria. None of the both group patients had developed any major cardiac event. No significant changes were observed regarding ST-T wave abnormalities, arrhythmias, or QT interval. None of the both group patients developed echocardiographic regional wall motion abnormalities at baseline or at study end. Systolic function parameters showed minute nonsignificant changes over study visits. Diastolic function parameters showed nonsignificant changes between baseline and 6-month and 12-month visits.CONCLUSIONSThe DAAs used in combination regimen with interferon or used orally in combination do not significantly affect the cardio-vascular system.

show abstract

“…The mean age of these six patients was 63 years and five of them had previous cardiovascular incidents. Friess et al prospectively assessed cardiac rhythm disturbances in 20 patients receiving INF-gamma (23). They documented no significant change in the average heart rate, maximal heart rate, ventricular ectopy and supraventricular ectopy during interferon treatment.…”

Section: Discussionmentioning

confidence: 99%

Interferon‐alpha does not cause significant cardiac dysfunction in patients with chronic active hepatitis

Kadayıfçı

Aytemir

Arslan

et al. 1997

Liver

View full text Add to dashboard Cite

: The cardiac adverse effects of interferon (INF) treatment have been reported recently in various clinical trials of INF. In this study, the cardiac effects of recombinant INF‐alpha treatment were evaluated prospectively in a group of patients with chronic active viral hepatitis (CAH). Sixteen patients with CAH type B, 14 patients with CAH type C and one patients with CAH type D were included in this study, and 4.5, 3 and 9 MU of recombinant INF‐alpha‐2a was administrated three times a week to these patients, respectively. The durations of treatment were 6 months for CAH type B and C, and 12 months for type D. The cardiac status of all patients was evaluated and monitored with a detailed medical history, physical examination, electrocardiography (ECG), telecardiography, echocardiography and heart rate variability tests at the beginning of the study and at the first and sixth months of INF therapy and also 6 months after ceasing the therapy. The clinical evaluation of patients before the treatment revealed that three had hypertension, one had a past medical history of myocardial infarction, one had a prosthetic mitral valve replacement and another had left hemiblock in her ECG record. No significant changes and adverse effects were detected in clinical examination and cardiovascular tests of all patients, either in preexisting cardiovascular diseases, during therapy and after stopping the treatment. The cardiac adverse effects of INF reported in previous studies are questionable and we conclude that it can be used safely in CAH patients. Therefore, it should be kept in mind that fever and tachycardia may occur during the first and second weeks of INF therapy and patients with high risk for cardiac disease should be monitored closely in this period of treatment.

show abstract

Cardiovascular rhythm effects of gamma recombinant DNA interferon

Cited by 19 publications

References 9 publications

Arrhythmogenic and Inotropic Effects of Interferon Investigated in Perfused and in Vivo Rat Hearts. Influences of Cardiac Hypertrophy and Isoproterenol.

Arrhythmogenic and Inotropic Effects of Interferon Investigated in Perfused and in Vivo Rat Hearts. Influences of Cardiac Hypertrophy and Isoproterenol.

Effect of Chronic Hepatitis C Virus Treatment by Combination Therapy on Cardiovascular System

Interferon‐alpha does not cause significant cardiac dysfunction in patients with chronic active hepatitis

Contact Info

Product

Resources

About